Brian O Mahony/ X
Jul 12, 2026, 07:58
Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
Brian O Mahony, CEO of Irish Haemophilia Society, shared a post on X:
“Nogami ISTH 2026 NXT-007.
4 doses used in clinical trial.
FVIII equivalent varied from 13.8 percent to 93.1 percent.
Not sure any additional FVIII required-even for major surgery.”
Other posts featuring Brian O Mahony on Hemostasis Today.
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number